Japan’s Crossroads: PhRMA’s Scangos Warns Of Policy Change Fallout
This article was originally published in PharmAsia News
Executive Summary
The foreign research-based pharma industry in Japan is continuing to ramp up warnings about what it sees as possible negative changes to Japan's currently "stable and predictable" pricing and operating environment, with the new chairman of US group PhRMA the latest to weigh in on the debate.
You may also be interested in...
Pricey New HCV, Cancer Drugs Push Up Japan’s Health Care Costs
Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.
Oncology Dominates Japan Approvals, Though Overall Tally Is Lower
Although it approved fewer new products last fiscal year, Japan granted access to a number of important new therapies, including in oncology and several for the first time worldwide, helped by continuing reforms at its regulatory body.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.